A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards

Keyphrases

• Cardiotoxicity Screening 100%
• Screenings Standards 100%
• Human Pluripotent Stem Cell-derived Cardiomyocytes 100%
• Publication Standards 100%
• High-throughput Drug Discovery 100%
• Clinical Application 33%
• High-throughput Screening 33%
• Induced Pluripotent Stem Cells (iPSCs) 33%
• Regenerative Medicine 33%
• Personalized Medicine 33%
• Drug Discovery 33%
• Disease Modeling 33%
• Cardiomyocytes 33%
• Screening Assays 33%
• Cardiotoxicity 33%
• Pharmacogenomics 33%
• In Vitro Model 33%
• Pharmaceutical Industry 33%
• Attrition Rate 33%
• Human Pluripotent Stem Cells (hPSCs) 33%
• In Vitro Production 33%
• Somatic Tissues 33%
• Human Cardiac Progenitor Cells 33%
• Drug Discovery Screening 33%
• Preclinical Toxicity 33%
• Drug Attrition 33%
• Pluripotent Stem Cell-derived Cardiomyocytes 33%
• Toxicity Screening 33%

Biochemistry, Genetics and Molecular Biology

• Stem Cell 100%
• Cardiac Muscle Cell 100%
• Disease Modeling 33%
• Pharmacogenomics 33%
• Induced Pluripotent Stem Cell 33%
• High Throughput Screening 33%
• Progenitor Cell 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Cardiotoxicity 100%
• Drug Discovery 100%
• High-Throughput Screening 33%
• Pharmacogenomics 33%
• Disease 33%